Real-world data: Cancer and SARS-CoV-2 infection

Background: Madrid has been the epicenter of the SARS-CoV2 pandemic in Spain We analyzed the experience at our hospital with SARS-CoV2 infection and cancer patients (p) Methods: We analyzed our experience from March 1 to April 30 at the Puerta de Hierro University Hospital in Madrid Diagnosis of SARS-CoV2 infection was made by RT-PCR, suspected cases not confirmed were excluded Results: Overall in-hospital mortality cancer p with COVID-19 was 15 2% (95%CI, 6 3;5 2), similar to 12 7% (95%CI,11 1;4 4) with p=0 615 of the global COVID-19 hospitalised population and greater than that of patients admitted without SARS-CoV-2 infection during the same period 4 3% (95%CI;3 6;5 2) p<0 001 Among 653 patients receiving active cancer therapy during this period, 24 (3 7%) developed COVID-19 and required admission, 4 2% of were receiving chemotherapy, 9 5% immunotherapy and 2 1% targeted therapies Lung and breast cancer were the most frequent (26 1%), followed by colorectal (19 6%) and breast cancer No significant differences due to the cancer treatment received were observed Mortality in lung cancer patients was the highest (25%) The univariate analysis (between p who developed serious event vs those who did not), showed that higher Brescia, CURB-65 scale, lactate dehydrogenase (LDH) or C-reactive protein (CRP) levels at admission, the greater risk of developing severe complications (p<0 05) [Formula presented] Conclusions: Patients with cancer, especially lung cancer, and SARS-CoV2 infection have a worse overall prognosis than the general population Objective parameters such as LDH, CRP at admission, Brescia index or CURB-65 should alert us to a more serious evolution and suggest early an early intensive care unit (ICU) admission Legal entity responsible for the study: The authors Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest